Loading page
Loading page
Loading substance route
Limited empirical data; single insufflated dose of 60 mg documented as maximal experienced dose. Threshold, light, and moderate tiers remain uncharacterized for this route.
Recognized abuse potential led to international regulation in the late 1970s, though it is generally considered to have lower abuse potential and milder stimulant effects compared to other stimulants in its class.
Recreational use of pipradrol and its derivatives has been linked to cases of acute toxicity and at least three fatalities.
| Species | Route | Value |
|---|---|---|
| rat | oral | 180 mg/kg |
| mouse | oral | 120 mg/kg |
| rabbit | oral | 180 mg/kg |
Psychosis and hallucinations are reported very rarely. The drug is contraindicated in individuals with pre-existing psychotic states or schizophrenia as it may worsen these symptoms.
Convulsions are described as very rare and primarily associated with severe overdose cases.
Pipradrol was developed in the United States during the 1940s and received its patent in 1953. By the mid-1950s, it had entered the pharmaceutical market under the brand name Meratran, primarily positioned as an antidepressant. Its clinical utility expanded to include adjunct treatment for a range…
Controlled under the Misuse of Drugs Act 1971. Pipradrol and its derivatives were specifically brought under control in 2012 due to social and acute clinical harms associated with their use. Class C substances carry penalties of up to 2 years imprisonment for possession and up to 14 years for supply.
Controlled under the Controlled Substances Act. Banned from the late 1970s due to its abuse potential. Schedule IV classification indicates accepted medical use with lower abuse potential relative to Schedule III substances.
8 sources cited